Crimson Publishers Publish With Us Reprints e-Books Video articles


Gastroenterology Medicine & Research

The Potential Role of Circulating Inflammatory Cells in Predicting the Safety, Efficacy and Immune-related Adverse Events of Immune Check-point Inhibitors: A Narrative Review<

  • Open or CloseTibera K Rugambwa1,2*, Omar Abdihamid2,3,4, Miriam Kessy5 and Alphonce MK Nyalali6,7,8

    1Department of Internal Medicine, Mbeya Zonal Referral Hospital and Mbeya College of Health and Allied Sciences, University of Dar-es-salaam, Mbeya, Tanzania

    2Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China

    3HCGCCK Cancer Centre, Nairobi, Kenya

    4Garissa Cancer Centre, Garissa County, Kenya

    5Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, Hunan, China

    6Department of Neurosurgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.

    7Department of Neurosurgery, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan 250012, China

    8Department of Surgery, Songwe Regional Referral Hospital, Songwe 23, Mbeya, Tanzania

    *Corresponding author: Tibera K Rugambwa, Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China

Submission: March 09, 2023; Published: March 30, 2023

DOI: 10.31031/GMR.2023.07.000665

ISSN 2637-7632
Volume7 Issue3


Immune checkpoint blockade has influenced the course of cancer treatment with improved Overall Survival (OS) and durable responses in many malignancies. Despite these responses, their mechanism of action has brought different set of adverse events that are severe and life-threatening in a subset of patients. Moreover, not all patients have shown to benefit from this treatment although their tumors express U.S. Federal and Drug Administration (FDA) approved biomarkers i.e programmed cell Death Protein 1 (PD-1) and its ligand (PD-L1), Microsatellite Instability (MSI) and Tumor Mutation Burden (TMB). Limitations of these markers has stimulated further research to identify and incorporate other markers that could serve as an adjunct to the current approved ones. Circulating inflammatory cells are among biomarkers that have shown to have a prognostic and predictive value in determining treatment response to Immune Checkpoint Inhibitors (ICI) and risk of Immune-Related Adverse Events (irAEs). This review aims to provide more details on the key inflammatory cells that play a pivotal role in cancer progression and inhibition and how their interaction in the tumor micro-environment (TME) affects response to immune checkpoint blockade and predicting irAEs. Moreover examples of prognostic models that have incorporated these cells will be highlighted.

Keywords:Immune checkpoint inhibitors; Circulating inflammatory cells; Immune-related adverse events; Biomarkers; Efficacy; Safety

Get access to the full text of this article